Integrated Biosystems, Inc. Expands European Operations
Announces the Opening of Customer Support Facilities in France
Integrated Biosystems, Inc. (IBI), the world's leading supplier of controlled freeze-thaw technology to the biopharmaceutical industry, today announced that a new customer support and applications laboratory has been opened in Aubagne, near Marseille, France.
The laboratory is located in the facilities of STEDIM with whom IBI has formed a strategic partnership to develop and commercialize its patented freeze-thaw technology incorporating disposable containers for use in the manufacturing of biopharmaceuticals. STEDIM is a global company with twenty-five years experience in the design and manufacture of single use plastic containers for the world's largest healthcare and pharmaceutical companies.
Although IBI has maintained a research and development operation in France to develop new products with STEDIM, the new laboratory, with increased staffing, will be the center for technical and applications support for the company's growing number of customers in Europe.
"Europe is a very important market for us," commented Richard Eagling, General Manager, Europe. "We see a lot of opportunity for growth. Our new facility is an essential component in providing excellent service and support for our growing customer base."
The new applications center complements IBI's existing commercial organization which is headquartered in Fribourg, Switzerland. The company already sells its controlled freeze-thaw technology to many of the large pharmaceutical manufacturers in Europe. The first product line, consisting of stainless steel vessels and thermal control units, sold under the CryoFin brand, was introduced about three years ago in Europe. The new Celsius product line, which will allow customers to perform their freeze-thaw operations using single use containers manufactured by STEDIM, is currently being launched worldwide. IBI's technology is already an integral part of the manufacturing process of many of the major biopharmaceutical products on the market today. More and more of these products are being manufactured in Europe to support the European healthcare needs. In addition, many of the large global pharmaceutical companies look to Europe for additional manufacturing capacity to meet the high growth projections of the biopharmaceutical industry.
As this market continues to experience rapid growth, IBI will be well positioned to provide the necessary technical support aimed at optimizing the efficiency of the biopharmaceutical industry's process development and manufacturing operations.
Other news from the department business & finance
